Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis
Systemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original rese...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_96634 | ||
| 005 | 20230202 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230202s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-6122-6 | ||
| 020 | |a 9783036561219 | ||
| 020 | |a 9783036561226 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-6122-6 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 100 | 1 | |a Herrington, Gaya |4 auth | |
| 700 | 1 | |a Tomcik, Michal |4 edt | |
| 700 | 1 | |a Tomcik, Michal |4 oth | |
| 245 | 1 | 0 | |a Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (318 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Systemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original research manuscripts and five review articles included in this book highlights the most recent advances in this field and provides further elucidation of the pathogenesis, natural disease course, and treatment of this challenging disease. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a heat shock protein 90 | ||
| 653 | |a systemic sclerosis | ||
| 653 | |a established dermal fibrosis | ||
| 653 | |a treatment | ||
| 653 | |a pathogenesis | ||
| 653 | |a epigenetic mechanisms | ||
| 653 | |a miRNAs | ||
| 653 | |a calcinosis cutis | ||
| 653 | |a bisphosphonates | ||
| 653 | |a pamidronate | ||
| 653 | |a autoimmune connective tissue diseases | ||
| 653 | |a dermatomyositis | ||
| 653 | |a immune cells | ||
| 653 | |a anti-inflammatory | ||
| 653 | |a therapy | ||
| 653 | |a fibrosis | ||
| 653 | |a interleukin-6 | ||
| 653 | |a Tocilizumab | ||
| 653 | |a pulmonary fibrosis | ||
| 653 | |a interstitial lung disease | ||
| 653 | |a progressive fibrosing interstitial lung disease | ||
| 653 | |a lung function | ||
| 653 | |a body mass index | ||
| 653 | |a clinical trial | ||
| 653 | |a metabolomics | ||
| 653 | |a LC-MS/MS | ||
| 653 | |a ion mobility | ||
| 653 | |a kynurenine pathway | ||
| 653 | |a urea cycle | ||
| 653 | |a lipids | ||
| 653 | |a gut dysbiosis | ||
| 653 | |a pulmonary arterial hypertension (PAH) | ||
| 653 | |a biomarkers | ||
| 653 | |a miRNA | ||
| 653 | |a complement | ||
| 653 | |a myofibroblasts | ||
| 653 | |a macitentan | ||
| 653 | |a cough | ||
| 653 | |a pulmonary hypertension | ||
| 653 | |a predictors of treatment response | ||
| 653 | |a autoreactive B cells | ||
| 653 | |a autoantibodies | ||
| 653 | |a rituximab | ||
| 653 | |a aptamers | ||
| 653 | |a Seldeg | ||
| 653 | |a n/a | ||
| 653 | |a mixed connective tissue disease | ||
| 653 | |a systemic lupus erythematosus | ||
| 653 | |a Sjögren's syndrome | ||
| 653 | |a rheumatoid arthritis | ||
| 653 | |a idiopathic inflammatory myopathy | ||
| 653 | |a national delphi consensus | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6579 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/96634 |7 0 |z DOAB: description of the publication |